AFYAConsumer Defensive · Education & Training ServicesThe 8 Wall Street analysts covering Afya Ltd. hold a median 12-month price target of $16 — +49.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Afya Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Accruals (48): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (44): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AFYA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +49.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Citigroup | Upgrade | Buy | $16 → $12 |
| 3 Nov 2026 | JP Morgan | Maintains | Overweight | $19 → $18 |
| 7 Oct 2026 | JP Morgan | Upgrade | Overweight | $21 → $19 |
| 22 June 2026 | JP Morgan | Maintains | Neutral | $22 → $21 |
| 22 June 2026 | JP Morgan | Maintains | Neutral | — |
| 30 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Feb 2026 | B of A Securities | Downgrade | Neutral | — |
| 13 Feb 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 16 Jan 2026 | UBS | Downgrade | Neutral | — |
| 8 Jan 2026 | UBS | Maintains | Buy | — |
| 7 Jan 2026 | JP Morgan | Downgrade | Neutral | — |
| 8 Sept 2025 | JP Morgan | Upgrade | Overweight | — |
| 8 Sept 2025 | UBS | Upgrade | Buy | — |
| 29 July 2025 | Citigroup | Upgrade | Neutral | — |
| 12 June 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | Morgan Stanley | Downgrade | Underweight | — |
| 31 Jan 2025 | Citigroup | Downgrade | Sell | — |
| 17 Jan 2025 | JP Morgan | Maintains | Neutral | — |
| 3 Dec 2024 | Goldman Sachs | Initiates | Sell | — |
| 30 Aug 2024 | UBS | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AFYA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Afya Ltd. returned −22.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 64% of US stocks
Cheaper than 89% of US stocks
Cheaper than 71% of US stocks
Cheaper than 57% of US stocks
Higher than 42% of US stocks
Higher than 53% of US stocks
Higher than 75% of US stocks
Higher than 87% of US stocks
Higher than 83% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 98% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Afya Ltd. has a market value of $933.4M and an enterprise value of $564.2M.
Revenue in the twelve months to 30 June 2026: $3.8B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $797.9M, a 20.9% net margin.
Free cash flow in the twelve months to 30 June 2026: $1.3B.
Afya Ltd. spent $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: 6.4×; forward P/E: 5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 25.13%, paying out 41% of earnings.
Afya Ltd. employs 9,395 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Afya Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Afya does not have the two key ingredients it considers necessary for a likely earnings beat in the upcoming report. The item outlines key expectations for the report.
Why it matters — AFYA watchers may note the article’s cautious assessment of the likelihood of an earnings beat.
At Afya’s 2026 Afya Day, executives outlined plans to expand its healthcare education and digital-services ecosystem, including a proposed Yduqs merger, planned synergy capture, shareholder returns, and growth in medical education and physician-focused technology.
Why it matters — The strategy and proposed merger could shape Afya’s business expansion, potential synergies, and shareholder-return plans.
Afya Limited held an Analyst/Investor Day, as reflected in the transcript published by Seeking Alpha. The excerpt provides no details about the discussion.
Why it matters — The event is relevant to AFYA watchers as a source of company information, but the provided excerpt does not describe its contents.
Zacks Investment Research compares Afya and Universal Technical Institute, asking which of the two education stocks offers the better value opportunity. The excerpt poses the question but does not provide an answer.
Why it matters — AFYA watchers may find the comparison relevant when assessing Afya’s value relative to another education stock.
Zacks Investment Research says its stock-picking focus is the Zacks Rank system, which emphasizes earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends. The excerpt does not provide a specific assessment of Afya.
Why it matters — AFYA watchers may note the factors Zacks considers, but the excerpt gives no stock-specific conclusion about Afya.
The 8 Wall Street analysts covering Afya Ltd. have a median 12-month price target of $16, with estimates ranging from $14 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Afya Ltd., 5 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Afya Ltd. 84 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Afya Ltd. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +49.8% from the last close, and Ticker Nerd's factor model ranks Afya Ltd. 84 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Afya Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $18 over the next 12 months.
Afya Ltd. returned -22.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Afya (AFYA) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research says Afya does not have the two key ingredients it considers necessary for a likely earnings beat in the upcoming report. The item outlines key expectations for the report.
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools. Its business is organized around education services, digital content, residency preparatory and specialization programs, and medical practice solutions, giving it a broad role across the medical training lifecycle. The company serves medical students, practicing physicians, and healthcare professionals seeking educational content and professional support tools. Afya’s Class A common shares are one class of its publicly traded equity and carry standard voting and ownership rights within the company’s share structure.
9,395 employees · Brazil · https://www.afya.com.br
